Biotransformation of α-asarone by Alternaria longipes CGMCC 3.2875
Jian Zou,Shuai Zhang,Huan Zhao,Yong-Heng Wang,Zheng-Qun Zhou,Guo-Dong Chen,Dan Hu,Ning Li,Xin-Sheng Yao,Hao Gao,Jian ZOU,Shuai ZHANG,Huan ZHAO,Yong-Heng WANG,Zheng-Qun ZHOU,Guo-Dong CHEN,Dan HU,Ning LI,Xin-Sheng YAO,Hao GAO
DOI: https://doi.org/10.1016/s1875-5364(21)60088-2
IF: 3.887
2021-09-01
Chinese Journal of Natural Medicines
Abstract:Biotransformation of α-asarone by Alternaria longipes CGMCC 3.2875 yielded two pairs of new neolignans, (+) (7S, 8S, 7'S, 8'R) iso-magnosalicin (1a)/(-) (7R, 8R, 7'R, 8'S) iso-magnosalicin (1b) and (+) (7R, 8R, 7'S, 8'R) magnosalicin (2a)/(-) (7S, 8S, 7'R, 8'S) magnosalicin (2b), and four known metabolites, (±) acoraminol A (3), (±) acoraminol B (4), asaraldehyde (5), and 2, 4, 5-trimethoxybenzoic acid (6). Their structures, including absolute configurations, were determined by extensive analysis of NMR spectra, X-ray crystallography, and quantum chemical ECD calculations. The cytotoxic activity and Aβ<sub>42</sub> aggregation inhibitory activity of all the compounds were evaluated. Compound 2 displayed significant anti-Aβ<sub>42</sub> aggregation activity with an inhibitory rate of 60.81% (the positive control EGCG: 69.17%). In addition, the biotransformation pathway of α-asarone by Alternaria longipes CGMCC 3.2875 was proposed.
pharmacology & pharmacy,integrative & complementary medicine